Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
| Autor: | Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS, Attard, Gerhardt |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 8/10/2009, Vol. 27 Issue 23, p3742-3748, 7p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|